A phase 2 study of fixed therapy with pirtobrutinib and obinutuzumab in previously untreated chronic lymphocytic leukemia (POP)

The purpose of this study is to learn about possible initial treatments for chronic lymphocytic leukemia (CLL). This study will evaluate the investigational drug pirtobrutinib in combination with the commercially available drug obinutuzumab to treat CLL. The U.S. Food and Drug Administration (FDA) has approved pirtobrutinib for the treatment of CLL that has returned (relapsed) or is resistant to other treatments. Pirtobrutinib i is not FDA approved for the first-time treatment of CLL. The FDA has approved obinutuzumab for the

Are you Eligible? (Inclusion Criteria)

• Must be ≥18 years of age 2. Do you have the ability to take oral medication 3. Do you have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2? ECOG PS describes a patient's level of functioning in terms of ability to care for oneself, daily activities and physical ability.